April 2026
Every article Wellness Radar published in April 2026 — long-form research, protocols, and reference work. Most-recent first.
Orforglipron just became the first oral GLP-1 to match injectables
ATTAIN-1, ACHIEVE-3, ATTAIN-MAINTAIN. Eli Lilly's once-daily oral small-molecule GLP-1 cleared a clean sweep of Phase 3 trials. The numbers, the safety profile, the FDA timeline, and what an effective pill does to GLP…
GLP-1 Resistance: Why 1 in 10 People Don't Respond
A landmark 23andMe GWAS in Nature (April 2026) confirmed a GLP-1 receptor missense variant in roughly 1 in 10 users that blunts the receptor signal — limiting weight loss and glucose control. Here's what non-response …
Lean mass preservation on GLP-1s — the protein floor and resistance training case
The lean-mass loss critique of GLP-1 therapy is partially right and partially overstated. STEP, SURMOUNT, and Lundgren's exercise data — and the practical protein-and-training protocol that the trials support.
GLP-1 weight regain: what the trials actually show
STEP-4, SURMOUNT-4, and the off-treatment data. How much weight comes back when GLP-1 therapy stops — and what the trials say about preventing it.
GLP-1 compounding 2025 — the legal landscape after the shortage list
FDA removed semaglutide from the drug shortage list in February 2025. The 503A/503B compounding window narrowed, the Outsourcing Facilities Association lost its preliminary injunction, and the legitimate compounding l…
Magnesium Acts as Vitamin D's On/Off Switch — Here's What That Means
A 2025 randomized trial extended earlier RCT evidence: magnesium acts as a thermostat for vitamin D — raising levels when deficient, suppressing them when high. Here's the mechanism and protocol implication.
Next-gen incretins — retatrutide, cagrisema, orforglipron pipeline
The triple-agonist (retatrutide), the amylin+sema combo (cagrisema), and the oral small-molecule GLP-1 (orforglipron). Mechanism differences, phase-3 readouts, and what each one actually changes for prescribing.
CGMs for non-diabetics — what the wearable data actually tells you
Where CGM data is real signal, where it's noise, and where it's marketing. Interstitial lag, MARD in healthy adults, and the limited outcome evidence for Stelo, Lingo, Levels, and Veri.